Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	G Medical Innovations Holdings Limited
ARBN 617 204	743

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Yacov Geva
Date of last notice	13 June 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	1 Indirect 2 Indirect 3 Indirect 4 Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Beneficial holding held through and registered in the name of Bank Julius Baer & Co Ltd Beneficial holding held through custodian and registered in the name of HSBC Custody Nominees (Australia) Limited Beneficial holding held through custodian and registered in the name of J P Morgan Nominees Australia Pty Limited Direct
Date of change	18 July 2019
No. of securities held prior to change	1 49,745,275 Class C Performance Rights 2 3,672,000 fully paid ordinary shares 3 193,778,322 fully paid ordinary shares 4 14,706,719 fully paid ordinary shares

⁺ See chapter 19 for defined terms.

Class	Fully paid ordinary shares	
Number acquired	1. Nil 2. Nil 3. Nil 4. 14,532,771	
Number disposed	1. Nil 2. Nil 3. Nil 4. Nil	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil cash consideration. Issued in settlement of US\$2,000,000 of a loan outstanding. For further detail refer Annual General Meeting Notice of Meeting (lodged with ASX on 23 May 2019).	
No. of securities held after change	1 49,745,275 Class C Performance Rights 2 3,672,000 fully paid ordinary shares 3 193,778,322 fully paid ordinary shares 4 29,239,490 fully paid ordinary shares	
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	14,532,771 shares issued in settlement of US\$2,000,000 of a loan facility, as approved by shareholders at the shareholder meeting held 24 June 2019.	

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder	N/A
(if issued securities)	
Date of change	N/A
No. and class of securities to which	N/A
interest related prior to change	
Note: Details are only required for a contract in	
relation to which the interest has changed	
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	N/A

Part 3 – ⁺Closed period

Appendix 3Y Page 2 01/01/2011

⁺ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Were the interests in the securities or contracts detailed above	N/A
traded during a ⁺ closed period where prior written clearance	
was required?	
If so, was prior written clearance provided to allow the trade to	N/A
proceed during this period?	
If prior written clearance was provided, on what date was this	N/A
provided?	1,711

⁺ See chapter 19 for defined terms.